Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 4/20 | 0.86 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | CHAT | P28329 | 2/20 | 0.86 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.86 |
| ▸ | AURKA | O14965 | 2/20 | 0.86 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.86 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622339 | 0.99 | EP300 (0.86) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL14769751 | 0.98 | EP300 (0.88) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL19704092 | 0.96 | EP300 (0.91) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL9945414 | 0.96 | EP300 (0.91) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL18803179 | 0.96 | EP300 (0.91) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL16216009 | 0.95 | EP300 (0.86) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL16216000 | 0.95 | EP300 (0.86) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL29082633 | 0.94 | NAA50 (0.84) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL18179672 | 0.94 | EP300 (0.89) | EP300NAA50CHATKAT5AURKA | |
| SCHEMBL18803180 | 0.93 | EP300 (0.86) | EP300NAA50CHATKAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | EP300 3343/4885NAA50 1314/4885CHAT 2115/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | EP300 3343/4885NAA50 1314/4885CHAT 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.